SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-010087
Filing Date
2024-02-02
Accepted
2024-02-02 16:37:48
Documents
15
Period of Report
2024-02-01
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm245109d1_8k.htm   iXBRL 8-K 26271
  Complete submission text file 0001104659-24-010087.txt   243793

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20240201.xsd EX-101.SCH 3303
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20240201_def.xml EX-101.DEF 26897
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20240201_lab.xml EX-101.LAB 36508
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20240201_pre.xml EX-101.PRE 25521
16 EXTRACTED XBRL INSTANCE DOCUMENT tm245109d1_8k_htm.xml XML 5316
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 24592156
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)